Patents by Inventor Ute Hoch

Ute Hoch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING A TUMOR
    Publication number: 20210292415
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and a CD-122-biased agonist. In some embodiments, the tumor is derived from a melanoma, a renal cell carcinoma (RCC), a non-small cell lung carcinoma (NSCLC), a urothelial cancer (UC), a breast cancer, or any combination thereof.
    Type: Application
    Filed: November 6, 2018
    Publication date: September 23, 2021
    Applicants: Bristol-Myers Squibb Company, Nektar Therapeutics
    Inventors: Wendy L. CLEMENS, Jonathan ZALEVSKY, Ute HOCH, Mary TAGLIAFERRI
  • COMBINATION-BASED TREATMENT METHOD
    Publication number: 20200237747
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 30, 2020
    Inventors: Ute Hoch, Nancy Marie Burns, Deborah H. Charych
  • Combination-based treatment method
    Patent number: 10653689
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: May 19, 2020
    Assignee: Nektar Therapeutics
    Inventors: Ute Hoch, Nancy Marie Burns, Deborah H. Charych
  • Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
    Publication number: 20190049450
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor, and correlating the level of one or more tumor markers in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: October 3, 2018
    Publication date: February 14, 2019
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
    Patent number: 10132810
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 20, 2018
    Assignee: Nektar Therapeutics
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • METHOD FOR PREDICTING AND EVALUATING RESPONSIVENESS TO CANCER TREATMENT WITH DNA-DAMAGING CHEMOTHERAPEUTIC AGENTS
    Publication number: 20180095085
    Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
    Type: Application
    Filed: December 7, 2017
    Publication date: April 5, 2018
    Inventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darren W. Davis
  • Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
    Patent number: 9863949
    Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: January 9, 2018
    Inventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darren W. Davis
  • COMBINATION-BASED TREATMENT METHOD
    Publication number: 20160339013
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Application
    Filed: January 13, 2015
    Publication date: November 24, 2016
    Inventors: Ute Hoch, Nancy Marie Burns, Deborah H. Charych
  • Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
    Publication number: 20150309032
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 29, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Yen Lin CHIA, Ute HOCH, Alison HANNAH, Michael A. ELDON
  • Treatment of Patients Suffering from Cancer
    Publication number: 20140378404
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Application
    Filed: October 25, 2012
    Publication date: December 25, 2014
    Applicant: Nektar Therapeutics
    Inventors: Ute Hoch, Michael A. Eldon, Abraham C.F. Leung
  • METHOD FOR PREDICTING AND EVALUATING RESPONSIVENESS TO CANCER TREATMENT WITH DNA-DAMAGING CHEMOTHERAPEUTIC AGENTS
    Publication number: 20140357659
    Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
    Type: Application
    Filed: May 30, 2014
    Publication date: December 4, 2014
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darin W. Davis
  • AURORA KINASE INHIBITORS
    Publication number: 20110293745
    Abstract: The present invention provides Compound 1, solid forms thereof, compositions thereof, as Aurora kinase inhibitor for use as an oncology agent. The present invention also provides synthetic methods of preparing Compound 1 and intermediates thereto.
    Type: Application
    Filed: March 16, 2009
    Publication date: December 1, 2011
    Applicant: SUNESIS PHARMACEUTICALS, INC.
    Inventors: Ute Hoch, Jeffrey A. Silverman, Daniel C. Adelman